CI-1033, a pan-erbB tyrosine kinase inhibitor

Seminars in Oncology

Volumn 28, Issue 5 SUPPL. 16, 2001, Pages 80-85

  Slichenmyer, William J ^a   Elliott, William L ^a   Fry, David W ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANERTINIB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INSULIN RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE ERBB; PROTEIN TYROSINE KINASE ERBB3; PROTEIN TYROSINE KINASE ERBB4; PROTEIN TYROSINE KINASE INHIBITOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; LUNG NON SMALL CELL CANCER; MULTIGENE FAMILY; NONHUMAN; NUDE MOUSE; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; TOXICITY;

EID: 0035168761     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.28558     Document Type: Conference Paper

References (19)

1. The type 1 growth factor receptor family: New ligands and receptors and their role in breast cancer
2. The ErbB receptors as targets for breast cancer therapy
3. Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers: Implication for tumor biology and clinical behavior
4. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer
5. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: Progression from reversible to irreversible inhibitors
6. Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer
7. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/ neu overexpressing human breast cancer xenografts
8. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer
9. Targeting the epidermal growth factor receptor for therapy of carcinomas
10. The type I growth factor receptors in human breast cancer
11. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases
12. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer
13. Epidermal growth factor receptor inhibition in cancer therapy: Biology, rationale and preliminary clinical results
14. Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes
15. The ErbB signaling network: Receptor heterodimerization in development and cancer
16. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor
17. Biochemical and antiproliferative properties of 4-[ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor
18. Dominance of ErbB-1 heterodimers in lung epithelial cells overexpressing ErbB-2: Both ErbB-1 and ErbB-2 contribute significantly to tumorigenicity
19. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors